<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00251251</url>
  </required_header>
  <id_info>
    <org_study_id>FRN 63208</org_study_id>
    <secondary_id>FRN 63208</secondary_id>
    <nct_id>NCT00251251</nct_id>
  </id_info>
  <brief_title>Resynchronization/Defibrillation for Ambulatory Heart Failure Trial</brief_title>
  <acronym>RAFT</acronym>
  <official_title>Resynchronization/Defibrillation for Ambulatory Heart Failure Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ottawa Heart Institute Research Corporation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medtronic</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ottawa Heart Institute Research Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Congestive heart failure (CHF) is a common health problem that leads to frequent&#xD;
      hospitalizations and an increased death rate. In spite of advances in drug therapy, it&#xD;
      remains a significant public health problem. Recently, a new therapy has been developed for&#xD;
      advanced heart failure patients with a ventricular conduction abnormality. This new therapy,&#xD;
      called cardiac resynchronization (CRT), is a device which stimulates the atrium, the right&#xD;
      ventricle, and the left ventricle providing synchronization of the contraction of the heart&#xD;
      chambers. It is the addition of this therapy to an implantable cardioverter defibrillator&#xD;
      (ICD) that will be evaluated in this study. This study will compare whether the implantation&#xD;
      of this new therapy device, in combination with an implantable cardioverter defibrillator,&#xD;
      will reduce total mortality and hospitalizations for CHF.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cardiovascular mortality is decreasing in most industrial countries, however mortality for&#xD;
      congestive heart failure is increasing. The most important predictors of mortality in heart&#xD;
      failure patients are depressed left ventricular function, severity of symptoms (NYHA class),&#xD;
      and ventricular conduction abnormality manifested as wide QRS. Recent advances in&#xD;
      pharmacological therapy including ACE inhibitors, beta-blocker and spironolactone have&#xD;
      resulted in improvement of symptoms and reduction in mortality. Population epidemiological&#xD;
      studies demonstrated that mortality and hospitalization rate for heart failure remains very&#xD;
      high despite recent pharmacological therapeutic progress. Recent short-term clinical trials&#xD;
      demonstrated that cardiac resynchronization therapy (CRT) is effective in improving symptoms&#xD;
      of heart failure, functional capacity and quality of life in patients with moderate to severe&#xD;
      heart failure and conduction abnormality optimally treated with drug therapy. However, the&#xD;
      data for morbidity and mortality in mild to moderate heart failure is lacking.&#xD;
&#xD;
      The objective of this trial is to determine if the addition of CRT to optimal pharmacological&#xD;
      therapy and ICD is effect in reducing mortality and morbidity in patients with poor LV&#xD;
      function, wide QRS and mild to moderate heart failure symptoms.&#xD;
&#xD;
      This is a double-blinded randomized control trial. A total of 1800 patients with mild to&#xD;
      moderate heart failure symptoms, LVEF ≤ 30%, and QRS ≥ 120 ms will be included in the study.&#xD;
      Patients will be randomized to either &quot;ICD plus Optimal Medical Therapy (control)&quot; or&#xD;
      &quot;CRT/ICD plus Optimal Medical Therapy (experimental)&quot; in a 1:1 randomization ratio. Patients&#xD;
      in the control group will be implanted with a single or dual chamber ICD. Patients in the&#xD;
      experimental group will receive a device with the capabilities of CRT and ICD. Optimal&#xD;
      Medical Therapy will include ACE inhibitors and beta-blockers. Patients will be followed on a&#xD;
      regular basis and will have clinical evaluation, quality of life assessment, and six minute&#xD;
      walk tests performed. The primary outcome is a composite of total mortality and heart failure&#xD;
      hospitalization. Secondary outcome measures will include total mortality, cardiovascular&#xD;
      mortality, sudden arrhythmic death, health related quality of life and cost economics.&#xD;
      Patient accruement is scheduled for 4.5 years and a minimum follow of 18 months.&#xD;
&#xD;
      DFT sub study:&#xD;
&#xD;
      Overview of sub-study Design Patients participating in the RAFT trial, at participating&#xD;
      sites, will be randomized to have DFT testing or no testing at the time of device implant. Up&#xD;
      to 450 patients will be eligible for enrollment at Canadian and European centres. The study&#xD;
      will have two primary outcomes: a short-term safety outcome and a long-term efficacy outcome.&#xD;
      The safety outcome will be a composite of all adverse events potentially related to DFT that&#xD;
      occur within 30 days following ICD implant. The long-term efficacy outcome will be a&#xD;
      composite of failed first appropriate clinical ICD shock and sudden death. This pilot study&#xD;
      is intended primarily to confirm the anticipated rates of events and to demonstrate&#xD;
      feasibility of enrollment, but will not have statistical power to determine if&#xD;
      intra-operative DFT testing is associated with significant short-term risk. If complication&#xD;
      rates are as high as predicted and enrollment is feasible, then a larger study would be&#xD;
      justified to determine the impact of intra-operative DFT testing on long-term rates of failed&#xD;
      appropriated ICD shocks and sudden death. Events rates determined in this pilot study would&#xD;
      then be used to estimate the sample size of this larger study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2003</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary outcome is a composite of all cause total mortality and hospitalization for CHF</measure>
    <time_frame>Study end</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total mortality</measure>
    <time_frame>Study end</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular mortality</measure>
    <time_frame>Study end</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sudden arrhythmic death</measure>
    <time_frame>Study end</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progressive HF death</measure>
    <time_frame>Study end</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All cause hospitalization rate</measure>
    <time_frame>Study end</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CHF hospitalization rate</measure>
    <time_frame>Study end</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health related quality of life</measure>
    <time_frame>Study end</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost economics</measure>
    <time_frame>Study end</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1798</enrollment>
  <condition>Heart Failure, Congestive</condition>
  <arm_group>
    <arm_group_label>1. Optimal Medical therapy plus ICD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2. Optimal Medical Therapy plus CRT/ICD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Optimal Medical Therapy plus ICD</intervention_name>
    <description>ICD vs CRT/ICD</description>
    <arm_group_label>1. Optimal Medical therapy plus ICD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Optimal Medical Therapy plus CRT/ICD</intervention_name>
    <description>ICD vs CRT/ICD</description>
    <arm_group_label>2. Optimal Medical Therapy plus CRT/ICD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  New York Heart Association (NYHA) Class II&#xD;
&#xD;
          -  Left ventricular ejection fraction (LVEF) less than or equal to 30% by multigated&#xD;
             acquisition scan (MUGA)/catheterization OR LVEF less than or equal to 30% and LV end&#xD;
             diastolic dimension ≥ 60 mm (by echocardiogram) within 6 months prior to randomization&#xD;
&#xD;
          -  Intrinsic QRS complex width ≥ 120 ms OR paced QRS measurement ≥ 200 ms&#xD;
&#xD;
          -  ICD indication for primary or secondary prevention&#xD;
&#xD;
          -  Optimal heart failure pharmacological therapy&#xD;
&#xD;
          -  Normal sinus rhythm; OR chronic persistent atrial tachyarrhythmia with resting&#xD;
             ventricular heart rate ≤ 60 beats per minute (bpm) and 6 minute hall walk ventricular&#xD;
             heart rate of ≤ 90 bpm; OR chronic persistent atrial tachyarrhythmia with resting&#xD;
             ventricular heart rate &gt; 60 bpm and 6 minute hall walk ventricular heart rate of &gt; 90&#xD;
             bpm and booked for atrioventricular junction ablation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Intravenous inotropic agent in the last 4 days&#xD;
&#xD;
          -  Patients with a life expectancy of less than one year from non-cardiac cause&#xD;
&#xD;
          -  Expected to undergo cardiac transplantation within one year (status I)&#xD;
&#xD;
          -  In hospital patients who have acute cardiac or non-cardiac illness that requires&#xD;
             intensive care&#xD;
&#xD;
          -  Uncorrected or uncorrectable primary valvular disease&#xD;
&#xD;
          -  Restrictive, hypertrophic, or reversible form of cardiomyopathy&#xD;
&#xD;
          -  Severe primary pulmonary disease such as cor pulmonale&#xD;
&#xD;
          -  Tricuspid prosthetic valve&#xD;
&#xD;
          -  Patients with an existing ICD (patients with an existing pacemaker may be included if&#xD;
             the patients satisfy all other inclusion/exclusion criteria)&#xD;
&#xD;
          -  Coronary revascularization (coronary artery bypass graft surgery [CABG] or&#xD;
             percutaneous coronary intervention [PCI]) &lt; 1 month if previously determined LVEF &gt;&#xD;
             30%. Patients with a more recent revascularization can be included if a previously&#xD;
             determined LVEF was ≤ 30%.&#xD;
&#xD;
          -  Patients with an acute coronary syndrome including myocardial infarction (MI) can be&#xD;
             included if the patients have had a previous MI with LV dysfunction (LVEF ≤ 30%).&#xD;
&#xD;
          -  Patients included in another clinical trial that will affect the objectives of this&#xD;
             study&#xD;
&#xD;
          -  History of noncompliance to medical therapy&#xD;
&#xD;
          -  Unable or unwilling to provide informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anthony Tang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ottawa Heart Institute Research Corporation</affiliation>
  </overall_official>
  <overall_official>
    <last_name>George Wells, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ottawa Heart Institute Research Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sir Charles Gairdner Hospital</name>
      <address>
        <city>Perth</city>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Ziekenhuis</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Calgary/Foothill Hospital</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 2T9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alberta Heart Institute</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Paul's Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 1Y6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Victoria Cardiac Arrhythmia Trials</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <zip>V8R 4R2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NB Heart Centre Research Initiative</name>
      <address>
        <city>St. John</city>
        <state>New Brunswick</state>
        <zip>E2L 4L2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Hospital</name>
      <address>
        <city>St. Johns</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1B 3V6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth II</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 3A7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hamilton Health Sciences Centre</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8L 2X2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kingston General Hospital</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 2V7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Mary's Hospital</name>
      <address>
        <city>Kitchener</city>
        <state>Ontario</state>
        <zip>N2M 1B2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southlake Regional Health Care</name>
      <address>
        <city>Newmarket</city>
        <state>Ontario</state>
        <zip>L3Y 8C3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Ottawa Heart Institute</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1Y 4 W7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UHN Toronto General</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montreal Heart Institute</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 1C8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHUM Hopital Notre Dame</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L 4M1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGill University Health Centre</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3A 1A1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital du Sacre Coeur de Montreal</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4J 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Laval Hospital</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHUS Centre Hospitalier Universitaire de Sherbrooke</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skejby University Hospital</name>
      <address>
        <city>Aarhus</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zentralklinik</name>
      <address>
        <city>Bad Berka</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>J.W. Goethe University</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Giessen</name>
      <address>
        <city>Giessen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ludwigshafen</name>
      <address>
        <city>Ludwigshafen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Mainz</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isala Klinieken</name>
      <address>
        <city>Zwolle</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ege University</name>
      <address>
        <city>Izmir</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Turkey</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <study_first_submitted>November 8, 2005</study_first_submitted>
  <study_first_submitted_qc>November 8, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 9, 2005</study_first_posted>
  <last_update_submitted>June 15, 2012</last_update_submitted>
  <last_update_submitted_qc>June 15, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 18, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ottawa Heart Institute Research Corporation</investigator_affiliation>
    <investigator_full_name>Anthony Tang</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Congestive heart failure</keyword>
  <keyword>Multicentre randomized controlled trial</keyword>
  <keyword>Defibrillator</keyword>
  <keyword>Cardiac resynchronization</keyword>
  <keyword>Sudden death/mortality</keyword>
  <keyword>Hospitalization</keyword>
  <keyword>ICD indication</keyword>
  <keyword>NYHA Class II</keyword>
  <keyword>LVEF &lt;/equal to 30%</keyword>
  <keyword>QRS &gt;/equal to 120 ms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

